|
NR. 3(I)/2007
|
|
|
|
|
|
|
|
|
Inhibitory VEGF w
leczeniu neowaskularnej postaci zwyrodnienia plamki związanego z
wiekiem
VEGF Inhibitors in the Treatment of Neovascular Age-Related
Macular Degeneration
Halina Wykrota, Krzysztof
Trzciąkowski
Samodzielny Publiczny Szpital Kliniczny Nr 5
Śląskiego Uniwersytetu Medycznego w Katowicach
Dyrektor: prof. dr hab. n. med. Ariadna Gierek-Łapińska |
|
|
|
|
|
|
|
| Summary: |
Treatment of neovascular
age-related macular degeneration (AMD) in past century
was limited to thermal laser photocoagulation only.
Implementation of photodynamic therapy with verteporfin
in 2000 improved safety and efficacy of the treatment
but still the method is based on existing fibrovascular
membranes damage. Additionally none of those methods are
fully effective and recurrence rate was very high as
well as not all subtypes of CNV are eligible to
treatment. The new approach to CNV treatment is to
discover and eliminate factors, which are directly
affecting CNV development. Studies on the role that
angiogenesis plays in pathogenesis of the disease have
allowed to employ inhibitors of vascular endothelial
growth factor (VEGF) for the neovascular AMD treatment.
Numerous of anti-VEGF compounds are being developed in
pre-clinical or phase-1/2 clinical studies. Efficacy in
CNV closure of VEGF Trap that is a high affinity
antagonist of VEGF has been demonstrated recently. VEGF
Trap binds to all VEGF isoforms. Small interfering RNA
compound (siRNA) is under evaluation as VEGF mRNA
suppressor. One molecule of siRNA may potentially
silence a hundreds of VEGF mRNA. Two of anti-VEGF
medicine: pegaptanib and ranibizumab that are delivered
intravitreally have completed phase 3 of clinical trials.
It seems that treatment that can block different
isoforms of VEGF is effective in patients treated for
CNV due to AMD. Further research is needed to evaluate
which compound would have the best safety and efficacy
profile. Implementation of anti-VEGF therapy for
treatment of ocular diseases gave a new hope for
patients, who previously couldn’t be treated with any
method. |
| |
|
| Key words: |
age-related macular
degeneration, choroidal neovascularization, vascular
endothelial growth factor, pegaptanib, ranibizumab. |
|
|
|
|
|
|
|
|
